A randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study of brivekimig followed by a maintenance period in participants with moderate to severe hidradenitis suppurativa [BRIGHTEN] (NCT07170917)

The purpose of this study is to assess the efficacy and safety of brivekimig in a dose-ranging study of participants with moderate to severe Hidradenitis Suppurativa (HS). Participants will be in the study for up to 60 weeks and have the option to enter a long-term extension study for an additional 52 weeks. The treatment will be administered via subcutaneous injection (small injection into the abdomen) every two weeks.

Trial phase

Phase 2

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

Prof Johannes S Kern

Key inclusion data

INCLUSION: Participants with a diagnosis of moderate to severe HS for at least 6 months; Must have lesions present in at least two different spots on the body; Must have tried oral antibiotics for treatment of HS and had an inadequate response or intolerance. EXCLUSION: Known history of serious immunosuppression; Ongoing treatment with opioid analgesics for HS related pain.